NMR-based metabolomics study of canine bladder cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 11, 2012, Pages 1807-1814

  Zhang, Jian ^a   Wei, Siwei ^a   Liu, Lingyan ^b   Nagana Gowda, G A ^a   Bonney, Patty ^c   Stewart, Jane ^c   Knapp, Deborah W ^c,d   Raftery, Daniel ^a,d  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

^d Purdue University   (United States)

Author keywords

Biomarker; Bladder cancer; Dog; Metabolomics; Nuclear magnetic resonance spectroscopy; Transitional cell carcinoma

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETONE; CHOLINE; CITRIC ACID; METHYLGUANIDINE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; MALE; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TRANSITIONAL CELL CARCINOMA; URINALYSIS;

3-HYDROXYBUTYRIC ACID; ACETONE; ANIMALS; CARCINOMA, TRANSITIONAL CELL; CHOLINE; CITRIC ACID; DOGS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METHYLGUANIDINE; TUMOR MARKERS, BIOLOGICAL; UREA; URINARY BLADDER NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84865562020     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.08.001     Document Type: Article

References (53)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
2. Kitamura H., Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int. J. Clin. Oncol. 2006, 11:28-37.
3. Mitra A.P., Cote R.J. Molecular screening for bladder cancer: progress and potential. Nat. Rev. Urol. 2010, 7:11-20.
4. Schroeder G.L., Lorenzo-Gomez M.F., Hautmann S.H., Friedrich M.G., Ekici S., Huland H., Lokeshwar V. A side by side comparison of cytology and biomarkers for bladder cancer detection. J. Urol. 2004, 172:1123-1126.
5. Van Q.N., Veenstra T.D., Issaq H.J. Metabolic profiling for the detection of bladder cancer. Curr. Urol. Rep. 2011, 12:34-40.
6. Kaufman D.S., Shipley W.U., Feldman A.S. Bladder cancer. Lancet 2009, 374:239-249.
7. Morgan T.M., Keegan K.A., Clark P.E. Bladder cancer. Curr. Opin. Oncol. 2011, 23:275-282.
8. Lintula S., Hotakainen K. Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer. Expert Opin. Biol. Ther. 2010, 10:1169-1180.
9. Bryan R.T., Zeegers M.P., James N.D., Wallace D.M., Cheng K.K. Biomarkers in bladder cancer. BJU Int. 2009, 105:608-613.
10. Shariat S.F., Zippe C., Ludecke G., Boman H., Sanchez-Carbayo M., Casella R., Mian C., Friedrich M.G., Eissa S., Akaza H., Sawczuk I., Serretta V., Huland H., Hedelin H., Rupesh R., Miyanaga N., Sagalowsky A.I., Wians F., Roehrborn C.G., Lotan Y., Perrotte P., Benayoun S., Marberger M.J., Karakiewicz P.I. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 2005, 173:1518-1525.
11. Lotan Y., Elias K., Svatek R.S., Bagrodia A., Nuss G., Moran B., Sagalowsky A.I. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J. Urol. 2009, 182:52-57.
12. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
13. Gowda G.A., Zhang S., Gu H., Asiago V., Shanaiah N., Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 2008, 8:617-633.
14. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
15. Thysell E., Surowiec I., Hornberg E., Crnalic S., Widmark A., Johansson A.I., Stattin P., Bergh A., Moritz T., Antti H., Wikstrom P. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. PLoS One 2010, 5:e14175.
16. Asiago V.M., Alvarado L.Z., Shanaiah N., Gowda G.A., Owusu-Sarfo K., Ballas R.A., Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70:8309-8318.
17. Zhang J., Liu L., Wei S., Nagana Gowda G.A., Hammoud Z., Kesler K.A., Raftery D. Metabolomics study of esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 2011, 141:469-475.
18. Zhang S., Nagana Gowda G.A., Asiago V., Shanaiah N., Barbas C., Raftery D. Correlative and quantitative 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal. Biochem. 2008, 383:76-84.
19. Lanza I.R., Zhang S., Ward L.E., Karakelides H., Raftery D., Nair K.S. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 2010, 5:e10538.
20. Zhao X., Fritsche J., Wang J., Chen J., Rittig K., Schmitt-Kopplin P., Fritsche A., Haring H.U., Schleicher E.D., Xu G., Lehmann R. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 2010, 6:362-374.
21. Denery J.R., Nunes A.A., Hixon M.S., Dickerson T.J., Janda K.D. Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis. PLoS Negl. Trop. Dis. 2010, 4:e834.
22. Blasco H., Corcia P., Moreau C., Veau S., Fournier C., Vourc'h P., Emond P., Gordon P., Pradat P.F., Praline J., Devos D., Nadal-Desbarats L., Andres C.R. 1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One 2010, 5:e13223.
23. Pan Z., Gu H., Talaty N., Chen H., Shanaiah N., Hainline B.E., Cooks R.G., Raftery D. Principal component analysis of urine metabolites detected by NMR and DESI-MS in patients with inborn errors of metabolism. Anal. Bioanal. Chem. 2007, 387:539-549.
24. Verwaest K.A., Vu T.N., Laukens K., Clemens L.E., Nguyen H.P., Van Gasse B., Martins J.C., Van Der Linden A., Dommisse R. (1)H NMR based metabolomics of CSF and blood serum: a metabolic profile for a transgenic rat model of Huntington disease. Biochim. Biophys. Acta 2011, 1812:1371-1379.
25. Pan Z., Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem. 2007, 387:525-527.
26. Chan E.C.Y., Ng D.J.Y., Pasikanti K.K. Trend analysis of metabonomics and systematic review of metabonomics-derived cancer marker metabolites. Metabolomics 2011, 7:155-178.
27. Hyndman M.E., Mullins J.K., Bivalacqua T.J. Metabolomics and bladder cancer. Urol. Oncol. 2011, 29:558-561.
28. Issaq H.J., Nativ O., Waybright T., Luke B., Veenstra T.D., Issaq E.J., Kravstov A., Mullerad M. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 2008, 179:2422-2426.
29. Srivastava S., Roy R., Singh S., Kumar P., Dalela D., Sankhwar S.N., Goel A., Sonkar A.A. Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: a pilot study by 1H NMR spectroscopy. Cancer Biomark. 2010, 6:11-20.
30. Pasikanti K.K., Esuvaranathan K., Ho P.C., Mahendran R., Kamaraj R., Wu Q.H., Chiong E., Chan E.C. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J. Proteome Res. 2010, 9:2988-2995.
31. Kim J.W., Lee G., Moon S.M., Park M.J., Hong S.K., Ahn Y.H., Kim K.R., Paik M.J. Metabolomic screening and star pattern recognition by urinary amino acid profile analysis from bladder cancer patients. Metabolomics 2010, 6:202-206.
32. Huang Z., Lin L., Gao Y., Chen Y., Yan X., Xing J., Hang W. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell. Proteomics 2011, 10. (M111.007922).
33. Knapp D.W., Glickman N.W., Denicola D.B., Bonney P.L., Lin T.L., Glickman L.T. Naturally-occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol. Oncol. 2000, 5:47-59.
34. Knapp D.W. Animal Medels: Naturally Occurring Canine Urinary Bladder Cancer. Textbook of Bladder Cancer 2006, 171-175. Taylor and Francis, Oxon, UK. S.P. Lerner, M.P. Schoenberg, C.N. Sternberg (Eds.).
35. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8:147-156.
36. Henry C.J., McCaw D.L., Turnquist S.E., Tyler J.W., Bravo L., Sheafor S., Straw R.C., Dernell W.S., Madewell B.R., Jorgensen L., Scott M.A., Higginbotham M.L., Chun R. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin. Cancer Res. 2003, 9:906-911.
37. Dhawan D., Craig B.A., Cheng L., Snyder P.W., Mohammed S.I., Stewart J.C., Zheng R., Loman R.A., Foster R.S., Knapp D.W. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol. Cancer Ther. 2010, 9:1371-1377.
38. Dhawan D., Ramos-Vara J.A., Stewart J.C., Zheng R., Knapp D.W. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol. Oncol. Semin. Orig. Investig. 2009, 27:284-292.
39. TNM Classification of Tumors in Domestic Animals 1980, World Health Organization, Geneva. 1st ed. L.N. Owen (Ed.).
40. Carrola J., Rocha C.M., Barros A.S., Gil A.M., Goodfellow B.J., Carreira I.M., Bernardo J., Gomes A., Sousa V., Carvalho L., Duarte I.F. Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J. Proteome Res. 2011, 10:221-230.
41. Patronek G.J., Waters D.J., Glickman L.T. Comparative longevity of pet dogs and humans: implications for gerontology research. J. Gerontol. A Biol. Sci. Med. Sci. 1997, 52:B171-B178.
42. Lindon J.C., Nicholson J.K., Everett J.R. NMR Spectroscopy of Biofluids. Annual Reports on NMR Spectroscopy 1999, 38:1-88.
43. Wang Y., Lawler D., Larson B., Ramadan Z., Kochhar S., Holmes E., Nicholson J.K. Metabonomic investigations of aging and caloric restriction in a life-long dog study. J. Proteome Res. 2007, 6:1846-1854.
44. Forbes G.B., Bruining G.J. Urinary creatinine excretion and lean body mass. Am. J. Clin. Nutr. 1976, 29:1359-1366.
45. Beckmann M., Enot D.P., Overy D.P., Scott I.M., Jones P.G., Allaway D., Draper J. Metabolite fingerprinting of urine suggests breed-specific dietary metabolism differences in domestic dogs. Br. J. Nutr. 2010, 103:1127-1138.
46. Rantalainen M., Cloarec O., Beckonert O., Wilson I.D., Jackson D., Tonge R., Rowlinson R., Rayner S., Nickson J., Wilkinson R.W., Mills J.D., Trygg J., Nicholson J.K., Holmes E. Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. J. Proteome Res. 2006, 5:2642-2655.
47. Tisdale M.J. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 1997, 13:1-7.
48. Lean C.L., Newland R.C., Ende D.A., Bokey E.L., Smith I.C., Mountford C.E. Assessment of human colorectal biopsies by 1H MRS: correlation with histopathology. Magn. Reson. Med. 1993, 30:525-533.
49. Chan E.C., Koh P.K., Mal M., Cheah P.Y., Eu K.W., Backshall A., Cavill R., Nicholson J.K., Keun H.C. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 2009, 8:352-361.
50. Bianchi L., De Micheli E., Bricolo A., Ballini C., Fattori M., Venturi C., Pedata F., Tipton K.F., Della Corte L. Extracellular levels of amino acids and choline in human high grade gliomas: an intraoperative microdialysis study. Neurochem. Res. 2004, 29:325-334.
51. Lyng H., Sitter B., Bathen T.F., Jensen L.R., Sundfor K., Kristensen G.B., Gribbestad I.S. Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 2007, 7:11.
52. Sussulini A., Kratzin H., Jahn O., Banzato C.E., Arruda M.A., Becker J.S. Metallomics studies of human blood serum from treated bipolar disorder patients. Anal. Chem. 2010, 82:5859-5864.
53. Ienaga K., Nakamura K., Fujisawa T., Fukunaga Y., Nihei H., Narita M., Tomino Y., Sanaka T., Aoyagi K., Nakano K., Koide H. Urinary excretion of creatol, an in vivo biomarker of hydroxyl radical, in patients with chronic renal failure. Ren. Fail. 2007, 29:279-283.